Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease

Vincent Yi Fong Su, Yu Sheng Chang, Yu Wen Hu, Man Hsin Hung, Shuo Ming Ou, Fa Yauh Lee, Kun Ta Chou, Kuang Yao Yang, Diahn Warng Perng, Tzeng Ji Chen, Chia Jen Liu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Beta (b)-blockers are under-prescribed in patients with heart failure (HF) and concurrent chronic obstructive pulmonary disease (COPD) due to concerns about adverse pulmonary effects and a poor understanding of the effects of these drugs. We aimed to evaluate the survival effects of b-blockers in patients with coexistent HF and COPD. Using the Taiwan National Health Insurance Research Database, we conducted a nationwide population-based study. Patients with coexistent HF and COPD diagnosed between 2000 and 2009 were enrolled. Doses of the 3 b-blockers proven to be beneficial to HF (carvedilol, bisoprolol, and metoprolol) during the study period were extracted. The primary endpoint was cumulative survival. Patients were followed until December 31, 2009. The study included 11,558 subjects, with a mean follow-up period of 4.07 years. After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR)1/40.76, 95% confidence interval (CI)=0.59-0.97, P=0.030; high dose: adjusted HR=0.40, 95% CI=0.26-0.63, P

Original languageEnglish
Article numbere2427
JournalMedicine (United States)
Volume95
Issue number5
DOIs
Publication statusPublished - 2016

Fingerprint

Bisoprolol
Metoprolol
Chronic Obstructive Pulmonary Disease
Heart Failure
Survival
Confidence Intervals
National Health Programs
Taiwan
Comorbidity
carvedilol
Databases
Lung
Research
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. / Su, Vincent Yi Fong; Chang, Yu Sheng; Hu, Yu Wen; Hung, Man Hsin; Ou, Shuo Ming; Lee, Fa Yauh; Chou, Kun Ta; Yang, Kuang Yao; Perng, Diahn Warng; Chen, Tzeng Ji; Liu, Chia Jen.

In: Medicine (United States), Vol. 95, No. 5, e2427, 2016.

Research output: Contribution to journalArticle

Su, Vincent Yi Fong ; Chang, Yu Sheng ; Hu, Yu Wen ; Hung, Man Hsin ; Ou, Shuo Ming ; Lee, Fa Yauh ; Chou, Kun Ta ; Yang, Kuang Yao ; Perng, Diahn Warng ; Chen, Tzeng Ji ; Liu, Chia Jen. / Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. In: Medicine (United States). 2016 ; Vol. 95, No. 5.
@article{95df8ed4f1eb44f0af6c221ff93ef93c,
title = "Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease",
abstract = "Beta (b)-blockers are under-prescribed in patients with heart failure (HF) and concurrent chronic obstructive pulmonary disease (COPD) due to concerns about adverse pulmonary effects and a poor understanding of the effects of these drugs. We aimed to evaluate the survival effects of b-blockers in patients with coexistent HF and COPD. Using the Taiwan National Health Insurance Research Database, we conducted a nationwide population-based study. Patients with coexistent HF and COPD diagnosed between 2000 and 2009 were enrolled. Doses of the 3 b-blockers proven to be beneficial to HF (carvedilol, bisoprolol, and metoprolol) during the study period were extracted. The primary endpoint was cumulative survival. Patients were followed until December 31, 2009. The study included 11,558 subjects, with a mean follow-up period of 4.07 years. After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR)1/40.76, 95{\%} confidence interval (CI)=0.59-0.97, P=0.030; high dose: adjusted HR=0.40, 95{\%} CI=0.26-0.63, P",
author = "Su, {Vincent Yi Fong} and Chang, {Yu Sheng} and Hu, {Yu Wen} and Hung, {Man Hsin} and Ou, {Shuo Ming} and Lee, {Fa Yauh} and Chou, {Kun Ta} and Yang, {Kuang Yao} and Perng, {Diahn Warng} and Chen, {Tzeng Ji} and Liu, {Chia Jen}",
year = "2016",
doi = "10.1097/MD.0000000000002427",
language = "English",
volume = "95",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease

AU - Su, Vincent Yi Fong

AU - Chang, Yu Sheng

AU - Hu, Yu Wen

AU - Hung, Man Hsin

AU - Ou, Shuo Ming

AU - Lee, Fa Yauh

AU - Chou, Kun Ta

AU - Yang, Kuang Yao

AU - Perng, Diahn Warng

AU - Chen, Tzeng Ji

AU - Liu, Chia Jen

PY - 2016

Y1 - 2016

N2 - Beta (b)-blockers are under-prescribed in patients with heart failure (HF) and concurrent chronic obstructive pulmonary disease (COPD) due to concerns about adverse pulmonary effects and a poor understanding of the effects of these drugs. We aimed to evaluate the survival effects of b-blockers in patients with coexistent HF and COPD. Using the Taiwan National Health Insurance Research Database, we conducted a nationwide population-based study. Patients with coexistent HF and COPD diagnosed between 2000 and 2009 were enrolled. Doses of the 3 b-blockers proven to be beneficial to HF (carvedilol, bisoprolol, and metoprolol) during the study period were extracted. The primary endpoint was cumulative survival. Patients were followed until December 31, 2009. The study included 11,558 subjects, with a mean follow-up period of 4.07 years. After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR)1/40.76, 95% confidence interval (CI)=0.59-0.97, P=0.030; high dose: adjusted HR=0.40, 95% CI=0.26-0.63, P

AB - Beta (b)-blockers are under-prescribed in patients with heart failure (HF) and concurrent chronic obstructive pulmonary disease (COPD) due to concerns about adverse pulmonary effects and a poor understanding of the effects of these drugs. We aimed to evaluate the survival effects of b-blockers in patients with coexistent HF and COPD. Using the Taiwan National Health Insurance Research Database, we conducted a nationwide population-based study. Patients with coexistent HF and COPD diagnosed between 2000 and 2009 were enrolled. Doses of the 3 b-blockers proven to be beneficial to HF (carvedilol, bisoprolol, and metoprolol) during the study period were extracted. The primary endpoint was cumulative survival. Patients were followed until December 31, 2009. The study included 11,558 subjects, with a mean follow-up period of 4.07 years. After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR)1/40.76, 95% confidence interval (CI)=0.59-0.97, P=0.030; high dose: adjusted HR=0.40, 95% CI=0.26-0.63, P

UR - http://www.scopus.com/inward/record.url?scp=84958818874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958818874&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000002427

DO - 10.1097/MD.0000000000002427

M3 - Article

C2 - 26844454

AN - SCOPUS:84958818874

VL - 95

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 5

M1 - e2427

ER -